Radius Health, Inc. is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company's lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Company's clinical pipeline also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug elacestrant (RAD1901) for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Its RAD140 is a non-steroidal, selective androgen receptor modulator (SARM). RAD140 is under development for potential use in hormone receptor positive breast cancer.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:RDUS
- CUSIP: N/A
- Web: www.radiuspharm.com
Capitalization:- Market Cap: $1.56 billion
- Outstanding Shares: 43,504,000
Average Prices:- 50 Day Moving Avg: $41.97
- 200 Day Moving Avg: $40.13
- 52 Week Range: $31.58 - $59.22
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -8.42
- P/E Growth: -0.15
Sales & Book Value:- Annual Revenue: $980,000.00
- Price / Sales: 1,591.45
- Book Value: $4.77 per share
- Price / Book: 7.52
Profitability:- EBIDTA: ($225,190,000.00)
- Return on Equity: -79.46%
- Return on Assets: -71.59%
Debt:- Current Ratio: 7.04%
- Quick Ratio: 6.99%
Misc:- Average Volume: 1.15 million shs.
- Beta: 1.32
- Short Ratio: 9.34
Frequently Asked Questions for Radius Health (NASDAQ:RDUS)
What is Radius Health's stock symbol?
Radius Health trades on the NASDAQ under the ticker symbol "RDUS."
How were Radius Health's earnings last quarter?
Radius Health, Inc. (NASDAQ:RDUS) announced its quarterly earnings data on Thursday, August, 3rd. The company reported ($1.58) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.35) by $0.23. The business had revenue of $0.98 million for the quarter, compared to analyst estimates of $1.96 million. During the same quarter in the previous year, the business posted ($1.01) EPS. View Radius Health's Earnings History.
Where is Radius Health's stock going? Where will Radius Health's stock price be in 2017?
7 brokerages have issued 1-year price objectives for Radius Health's shares. Their forecasts range from $24.00 to $85.00. On average, they anticipate Radius Health's share price to reach $53.60 in the next year. View Analyst Ratings for Radius Health.
What are analysts saying about Radius Health stock?
Here are some recent quotes from research analysts about Radius Health stock:
- 1. According to Zacks Investment Research, "The company’s wider-than-expected loss in the second quarter was disappointing as expenses continue to increase with the launch of Tymlos. The FDA’s approval of Radius Health’s lead candidate, Tymlos, is a significant boost for the company. Although the osteoporosis market in the U.S. has a great potential as approximately 1.4 million postmenopausal women in the U.S. experience an osteoporotic fracture each year, Tymlos is expected to face significant competition from Eli Lilly &Co's Forteo and Amgen’s Prolia. Further, the company suffered a setback when the CHMP issued a second Day-180 List of Outstanding Issues to its MAA for Eladynos in Europe. While Radius' efforts in developing its pipeline are encouraging, we note that most of its candidates are in their early or mid stages of development. On a positive note, the company’ shares have outperformed the industry year to date." (8/8/2017)
- 2. Canaccord Genuity analysts commented, "Date and time of first dissemination: July 31, 2017, 12:01 ET Date and time of production: July 31, 2017, 12:01 ET Target Price / Valuation Methodology: Radius Health – RDUS Our $85 price target is based on a probability adjusted EV/S methodology." (7/31/2017)
- 3. Cantor Fitzgerald analysts commented, "RDUS shares are rallying this morning (+2%) on FDA approval of TYMLOS (abaloparatide-SC) ahead of expectations, as the extended PDUFA was June." (4/28/2017)
Who are some of Radius Health's key competitors?
Some companies that are related to Radius Health include AveXis (AVXS), Juno Therapeutics (JUNO), Agios Pharmaceuticals (AGIO), BeiGene (BGNE), Intercept Pharmaceuticals (ICPT), GW Pharmaceuticals PLC (GWPH), China Biologic Products (CBPO), Ultragenyx Pharmaceutical (RARE), Spark Therapeutics (ONCE), Sarepta Therapeutics (SRPT), Loxo Oncology (LOXO), Axovant Sciences (AXON), Prothena Corporation PLC (PRTA), Aerie Pharmaceuticals (AERI), NovoCure Limited (NVCR), Halozyme Therapeutics (HALO), Array BioPharma (ARRY) and Lexicon Pharmaceuticals (LXRX).
Who are Radius Health's key executives?
Radius Health's management team includes the folowing people:
- Kurt C. Graves, Independent Chairman of the Board
- Jesper Hoiland, President, Chief Executive Officer, Director
- Jose Carmona, Chief Financial Officer, Principal Accounting Officer, Treasurer
- Gary Hattersley Ph.D., Senior Vice President, Chief Scientific Officer
- Brent Hatzis-Schoch, Senior Vice President, General Counsel, Secretary
- Lorraine A. Fitzpatrick M.D., Chief Medical Officer
- David P. Snow, Chief Commercial Officer
- Gregory Williams Ph.D., Chief Development Officer
- Alan H. Auerbach, Independent Director
- Willard H. Dere M.D., Independent Director
Who owns Radius Health stock?
Radius Health's stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (12.00%), BB Biotech AG (11.62%), MPM Asset Management LLC (8.96%), Farallon Capital Management LLC (8.47%), Vanguard Group Inc. (7.25%) and BlackRock Inc. (6.67%). Company insiders that own Radius Health stock include Gary Hattersley, Growth N V Biotech and Rob Ward. View Institutional Ownership Trends for Radius Health.
Who sold Radius Health stock? Who is selling Radius Health stock?
Radius Health's stock was sold by a variety of institutional investors in the last quarter, including Bain Capital Public Equity Management LLC, FMR LLC, OxFORD Asset Management LLP, Wells Fargo & Company MN, JPMorgan Chase & Co., Fiera Capital Corp, Bank of Nova Scotia and Alliancebernstein L.P.. View Insider Buying and Selling for Radius Health.
Who bought Radius Health stock? Who is buying Radius Health stock?
Radius Health's stock was purchased by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, TimesSquare Capital Management LLC, BB Biotech AG, RA Capital Management LLC, BlackRock Inc., State Street Corp, Vanguard Group Inc. and Capital Fund Management S.A.. View Insider Buying and Selling for Radius Health.
How do I buy Radius Health stock?
Shares of Radius Health can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Radius Health's stock price today?
One share of Radius Health stock can currently be purchased for approximately $35.85.
MarketBeat Community Rating for Radius Health (NASDAQ RDUS)MarketBeat's community ratings are surveys of what our community members think about Radius Health and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Radius Health (NASDAQ:RDUS) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Sell Rating, 2 Hold Ratings, 4 Buy Ratings |
| Consensus Rating: | Hold (Score: 2.43) |
| Consensus Price Target: | $53.60 (49.51% upside) |
Analysts' Ratings History for Radius Health (NASDAQ:RDUS)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 8/9/2017 | Jefferies Group LLC | Reiterated Rating | Hold | $34.00 -> $38.00 | High |  |
| 7/31/2017 | Canaccord Genuity | Set Price Target | Buy | $85.00 | Medium | |
| 7/23/2017 | Cantor Fitzgerald | Set Price Target | Buy | $58.00 | Medium | |
| 5/24/2017 | Maxim Group | Set Price Target | Sell | $24.00 | Low | |
| 5/15/2017 | HC Wainwright | Reiterated Rating | Buy | $63.00 | Low | |
| 5/2/2017 | Cowen and Company | Downgrade | Outperform -> Market Perform | | Low | |
| 3/11/2017 | J P Morgan Chase & Co | Reiterated Rating | Buy | | Medium | |
| 3/30/2016 | Goldman Sachs Group, Inc. (The) | Initiated Coverage | Neutral | $37.00 | N/A | |
| 1/25/2016 | Bank of America Corporation | Reiterated Rating | Buy | $89.00 | N/A | |
(Data available from 8/21/2015 forward)
Earnings History for Radius Health (NASDAQ:RDUS)Earnings History by Quarter for Radius Health (NASDAQ RDUS)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/3/2017 | Q2 2017 | ($1.35) | ($1.58) | $1.96 million | $0.98 million | View | Listen | |
| 5/4/2017 | Q1 2017 | ($1.18) | ($1.32) | | | View | Listen | |
| 2/23/2017 | Q416 | ($1.34) | ($1.22) | | | View | N/A | |
| 11/3/2016 | Q316 | ($1.03) | ($1.07) | $0.75 million | | View | N/A | |
| 8/4/2016 | Q216 | ($0.95) | ($1.01) | | | View | N/A | |
| 5/5/2016 | Q116 | ($0.74) | ($0.94) | | | View | N/A | |
| 2/25/2016 | Q415 | ($0.64) | ($0.77) | | | View | Listen | |
| 11/5/2015 | Q315 | ($0.58) | ($0.68) | | | View | N/A | |
| 8/6/2015 | Q215 | ($0.52) | ($0.61) | | | View | N/A | |
| 5/6/2015 | Q115 | ($0.52) | ($0.47) | | | View | N/A | |
| 3/10/2015 | Q414 | ($0.63) | ($0.55) | | | View | N/A | |
| 11/10/2014 | Q314 | ($0.65) | ($0.59) | | | View | N/A | |
| 8/12/2014 | Q2 | ($0.89) | ($2.22) | $16.24 million | $10.62 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Radius Health (NASDAQ:RDUS)2017 EPS Consensus Estimate: ($4.82)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.94) | ($0.94) | ($0.94) |
| Q2 2017 | 1 | ($1.37) | ($1.37) | ($1.37) |
| Q3 2017 | 1 | ($1.31) | ($1.31) | ($1.31) |
| Q4 2017 | 1 | ($1.20) | ($1.20) | ($1.20) |
(Data provided by Zacks Investment Research)
Dividend History for Radius Health (NASDAQ:RDUS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Radius Health (NASDAQ:RDUS)Insider Ownership Percentage: 15.00%
Institutional Ownership Percentage: 97.66%
Insider Trades by Quarter for Radius Health (NASDAQ:RDUS)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/16/2017 | Growth N V Biotech | Major Shareholder | Buy | 60,000 | $35.98 | $2,158,800.00 | |
| 8/10/2017 | Growth N V Biotech | Major Shareholder | Buy | 150,000 | $34.97 | $5,245,500.00 | |
| 5/30/2017 | Growth N V Biotech | Major Shareholder | Buy | 40,000 | $34.21 | $1,368,400.00 | |
| 5/25/2017 | Growth N V Biotech | Major Shareholder | Buy | 40,000 | $36.25 | $1,450,000.00 | |
| 5/18/2017 | Growth N V Biotech | Major Shareholder | Buy | 50,000 | $34.41 | $1,720,500.00 | |
| 5/17/2017 | Growth N V Biotech | Major Shareholder | Buy | 35,000 | $33.44 | $1,170,400.00 | |
| 5/12/2017 | Growth N V Biotech | Major Shareholder | Buy | 15,000 | $34.00 | $510,000.00 | |
| 5/9/2017 | Growth N V Biotech | Major Shareholder | Buy | 50,000 | $35.93 | $1,796,500.00 | |
| 5/8/2017 | Growth N V Biotech | Major Shareholder | Buy | 43,400 | $35.57 | $1,543,738.00 | |
| 5/2/2017 | Growth N V Biotech | Major Shareholder | Buy | 75,000 | $33.91 | $2,543,250.00 | |
| 5/1/2017 | Growth N V Biotech | Major Shareholder | Buy | 150,000 | $35.39 | $5,308,500.00 | |
| 3/21/2017 | Growth N V Biotech | Major Shareholder | Buy | 50,000 | $35.83 | $1,791,500.00 | |
| 3/17/2017 | Growth N V Biotech | Major Shareholder | Buy | 30,000 | $38.41 | $1,152,300.00 | |
| 3/15/2017 | Growth N V Biotech | Major Shareholder | Buy | 61,721 | $39.97 | $2,466,988.37 | |
| 3/10/2017 | Growth N V Biotech | Major Shareholder | Buy | 38,279 | $39.17 | $1,499,388.43 | |
| 1/22/2016 | Growth N V Biotech | Major Shareholder | Buy | 38,259 | $31.67 | $1,211,662.53 | |
| 1/13/2016 | Growth N V Biotech | Major Shareholder | Buy | 50,000 | $39.90 | $1,995,000.00 | |
| 11/12/2015 | Gary Hattersley | insider | Sell | 5,683 | $75.00 | $426,225.00 | |
| 11/3/2015 | Gary Hattersley | insider | Sell | 13,333 | $70.00 | $933,310.00 | |
| 10/23/2015 | Gary Hattersley | insider | Sell | 11,302 | $65.00 | $734,630.00 | |
| 10/21/2015 | Gary Hattersley | insider | Sell | 1,501 | $65.36 | $98,105.36 | |
| 10/21/2015 | Rob Ward | CEO | Sell | 50,000 | $61.99 | $3,099,500.00 | |
| 8/21/2015 | Growth N. V. Biotech | major shareholder | Buy | 100,000 | $64.00 | $6,400,000.00 | |
| 8/17/2015 | Kurt Graves | Director | Sell | 22,694 | $70.00 | $1,588,580.00 | |
| 7/6/2015 | Kurt Graves | Director | Sell | 25,000 | $69.48 | $1,737,000.00 | |
| 6/18/2015 | Kurt Graves | Director | Sell | 25,000 | $55.05 | $1,376,250.00 | |
| 5/1/2015 | Growth N V Biotech | Major Shareholder | Buy | 50,000 | $36.46 | $1,823,000.00 | |
| 4/29/2015 | Growth N V Biotech | Major Shareholder | Buy | 50,000 | $36.23 | $1,811,500.00 | |
| 4/28/2015 | Growth N V Biotech | Major Shareholder | Buy | 50,000 | $36.59 | $1,829,500.00 | |
| 4/27/2015 | Growth N V Biotech | Major Shareholder | Buy | 50,000 | $38.38 | $1,919,000.00 | |
| 3/6/2015 | Growth N V Biotech | Major Shareholder | Buy | 75,000 | $47.08 | $3,531,000.00 | |
| 2/25/2015 | Growth N V Biotech | Major Shareholder | Buy | 35,000 | $45.74 | $1,600,900.00 | |
| 6/11/2014 | Morana Jovan-Embiricos | Director | Buy | 587,500 | $8.00 | $4,700,000.00 | |
| 6/6/2014 | Growth N V Biotech | Major Shareholder | Buy | 1,000,000 | $8.00 | $8,000,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Radius Health (NASDAQ:RDUS)
Latest Headlines for Radius Health (NASDAQ:RDUS)
| Source: |
|
| Date | Headline |
|---|
 | Radius Health, Inc. – Value Analysis (NASDAQ:RDUS) : August 19, 2017
finance.yahoo.com - August 19 at 6:55 AM |
 | Radius Health, Inc. (RDUS) Major Shareholder Acquires $2,158,800.00 in Stock
www.americanbankingnews.com - August 18 at 1:22 PM |
| See what the IHS Markit Score report has to say about Radius Health Inc.
finance.yahoo.com - August 17 at 7:16 AM |
| Radius Health, Inc. (NASDAQ:RDUS) Cut to Sell at BidaskClub
www.americanbankingnews.com - August 13 at 12:10 AM |
| Growth N. V. Biotech Buys 150,000 Shares of Radius Health, Inc. (RDUS) Stock
www.americanbankingnews.com - August 11 at 1:22 PM |
 | Radius Health (RDUS) Presents At Canaccord Genuity 37th Annual Growth Conference - Slideshow
seekingalpha.com - August 11 at 7:59 AM |
| IHS Markit Score Update: Drop in demand for ETFs holding Radius Health Inc is a negative sign for its shares
finance.yahoo.com - August 11 at 7:59 AM |
| New National Survey Reveals 82 Percent of Postmenopausal Women Miss Critical Connection Between Osteoporosis and Bone Fractures
finance.yahoo.com - August 11 at 7:59 AM |
| Cantor Fitzgerald Weighs in on Radius Health, Inc.'s FY2017 Earnings (NASDAQ:RDUS)
www.americanbankingnews.com - August 10 at 9:32 AM |
| Jefferies Group LLC Reiterates "Hold" Rating for Radius Health, Inc. (NASDAQ:RDUS)
www.americanbankingnews.com - August 9 at 11:26 AM |
 | Radius Health Announces Pricing of $300 Million of 3.00% Convertible Senior Notes due 2024 - Nasdaq
www.nasdaq.com - August 9 at 6:52 AM |
| RSI Alert: Radius Health (RDUS) Now Oversold - Nasdaq
www.nasdaq.com - August 9 at 6:52 AM |
| Radius Health Announces Pricing of $300 Million of 3.00% Convertible Senior Notes due 2024
finance.yahoo.com - August 9 at 6:52 AM |
 | Radius Health (RDUS) Plans Offering of $300M of Convertible Senior Notes due 2024 - StreetInsider.com
www.streetinsider.com - August 8 at 6:37 AM |
| Radius Health (RDUS) Plans Offering of $300M of Convertible Senior Notes due 2024 - StreetInsider.com
www.streetinsider.com - August 8 at 6:37 AM |
| Radius Health, Inc. (NASDAQ:RDUS) Announces Quarterly Earnings Results
www.americanbankingnews.com - August 5 at 6:44 PM |
| Radius (RDUS) Q2 Loss Wider than Expected on Higher Expenses
finance.yahoo.com - August 5 at 6:34 AM |
| Radius Health's (RDUS) CEO Jesper Høiland on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 4 at 7:30 AM |
| Investor Network: Radius Health Inc to Host Earnings Call
finance.yahoo.com - August 4 at 7:30 AM |
| Radius Health Reports Second Quarter 2017 Financial and Operating Results and Provides Business Update
finance.yahoo.com - August 4 at 7:30 AM |
| Edited Transcript of RDUS earnings conference call or presentation 3-Aug-17 8:30pm GMT
finance.yahoo.com - August 4 at 7:30 AM |
| Radius Health, Inc. (RDUS) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - July 28 at 10:49 AM |
| Jefferies Group Comments on Radius Health, Inc.'s Q3 2017 Earnings (RDUS)
www.americanbankingnews.com - July 26 at 9:48 AM |
| Will Radius Health (RDUS) Disappoint this Earnings Season?
finance.yahoo.com - July 26 at 6:42 AM |
 | Apparently Fake Press Release Roils Radius Health Investors - Benzinga
www.benzinga.com - July 23 at 7:30 AM |
| Radius Health (RDUS) Announces CHMP Has Issued Second Day-180 List of Outstanding Issues in Regulatory ... - StreetInsider.com
www.streetinsider.com - July 22 at 8:11 AM |
| Brokerages Anticipate Radius Health, Inc. (NASDAQ:RDUS) Will Post Earnings of -$1.35 Per Share
www.americanbankingnews.com - July 19 at 2:44 PM |
| Head-To-Head Analysis: Intercept Pharmaceuticals (ICPT) vs. Radius Health (RDUS)
www.americanbankingnews.com - July 19 at 8:51 AM |
| Radius Health (RDUS) Names Jesper Hoiland as President and CEO - StreetInsider.com
www.streetinsider.com - July 18 at 7:46 AM |
 | Why Tesla Inc (TSLA), Radius Health Inc (RDUS) and Blue Apron ... - Investorplace.com
investorplace.com - July 18 at 7:46 AM |
| Radius Health (RDUS) Announces Pact for Abaloparatide-SC with Teijin Limited in Japan - StreetInsider.com
www.streetinsider.com - July 13 at 8:20 PM |
| Radius Health (RDUS) Announces Pact for Abaloparatide-SC with Teijin Limited in Japan
www.streetinsider.com - July 13 at 8:33 AM |
| Radius Health Announces License and Development Agreement for Abaloparatide-SC with Teijin Limited in Japan
finance.yahoo.com - July 13 at 8:33 AM |
| Zacks Investment Research Downgrades Radius Health, Inc. (NASDAQ:RDUS) to Sell
www.americanbankingnews.com - July 4 at 1:04 PM |
| Radius Health, Inc. (RDUS) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - July 3 at 11:24 AM |
| Radius Health, Inc. (RDUS) Upgraded to Buy by BidaskClub
www.americanbankingnews.com - June 27 at 8:22 PM |
| $1.96 Million in Sales Expected for Radius Health, Inc. (RDUS) This Quarter
www.americanbankingnews.com - June 25 at 9:44 AM |
| Radius Health, Inc. (RDUS) Upgraded at ValuEngine
www.americanbankingnews.com - June 24 at 11:32 PM |
| -$1.35 Earnings Per Share Expected for Radius Health, Inc. (RDUS) This Quarter
www.americanbankingnews.com - June 23 at 12:17 PM |
| Radius Health (RDUS) Shares Cross Above 200 DMA
www.nasdaq.com - June 21 at 3:29 AM |
 | Here's Why Radius Health Inc. Stock Is Jumping Today - Motley Fool
www.fool.com - June 6 at 8:56 PM |
| Radius Health (RDUS) Looks Good: Stock Adds 10.5% in Session
finance.yahoo.com - June 6 at 8:56 PM |
| Radius Health Inc (RDUS) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - June 6 at 8:42 AM |
| Radius Health Inc (RDUS) PT Set at $65.00 by Cantor Fitzgerald
www.americanbankingnews.com - June 5 at 10:34 PM |
| Radius Health (RDUS) Delivers Positive Data From A Fully Enrolled Ongoing ...
www.streetinsider.com - June 5 at 8:08 PM |
| Here's Why Radius Health Inc. Stock Is Jumping Today
finance.yahoo.com - June 5 at 8:08 PM |
| Here's Why Radius Health Inc. Stock Is Jumping Today
www.fool.com - June 5 at 4:50 PM |
| Jefferies Group LLC Reiterates "$34.00" Price Target for Radius Health Inc (RDUS)
www.americanbankingnews.com - June 5 at 2:26 PM |
| Cramer's lightning round: I'm blessing this chipmaker for a quick trade
finance.yahoo.com - June 4 at 7:39 PM |
| Radius Presents Positive Data From A Fully Enrolled Ongoing Phase I Study for Investigational Drug
www.nasdaq.com - June 4 at 9:23 AM |
Radius Health (RDUS) Chart for Monday, August, 21, 2017
